NVO Novo Nordisk A/S

$NVO earning likely irrelevant mid term unless big loss which I doubt. But market is sensing mgt not delusional about lackluster pipeline and just trying to buy time. It is obvious novo will not remain #2 beyond 2030 with the status quo.. I share the market hunch that novo will get over its insecurity from previous trials busts and see obvious mechanisms and data for a deal that will make it fairly face $LLY like the old days. $VKTX

$NVO If earnings go good (beat and raise) along with guidance for 2027/2028, a lot of money is going to flow into this name.. it's severely undervalued.

$NVO 25 years, QUARTERLY candles chart updated. It would be fantastic to end the year with that huge bullish signal activated. This is a buy & hold stock for long term investors. 4.5% dividend.

$NVO no rationale anymore and justitification for this to trade under 60USD after those numbers

$NVO interesting. I work for a large long term care pharmacy that services over 100 nursing homes and we use just as many Novo products as Lilly products. 🤔

$NVO 48B revenue per year..133b market cap..something is really broken here with the stock price. First step 65/70…fair value 100/110…this is the reality and we’ll see these value in the future 🥰

🚀 $NVO Q3: The numbers speak! 📈 Revenue: DKK 79.2B (+8.4% vs consensus) 💰 Adjusted EBIT: DKK 31.7B (+11.7%) 💊 Wegovy pill: DKK 5.39B (+68% QoQ) 🔥 2026 guidance RAISED to −2% to +2%! Strong execution. Rising expectations. 🚀💪🏻💥 📈

$NVO BREAKING $NVO Novo Nordisk Q3 sales hit DKK 79.2B, beating the DKK 73.6B estimate by 7.6% due to STRONG Wegovy pill sales

Novo Nordisk said its next-generation obesity drug CagriSema delivered an average 25% weight loss after 68 weeks among women with overweight or obesity, versus 3% with placebo, according to a post-trial analysis of approximately 2,300 women. A separate analysis of around 1,900 women found weight reductions of 26.7% in premenopausal, 24.8% in perimenopausal and 23.1% in postmenopausal patients, compared with about 2% for placebo across all groups. CagriSema also reduced abdominal fat across menopause stages. The results assume patients remained on treatment without interruptions and require further confirmation. In the broader Phase 3 trial, the drug produced average weight loss of 22.7% at 68 weeks versus 2.3% with placebo. CagriSema combines semaglutide, the active ingredient in Wegovy and Ozempic, with cagrilintide, which targets the amylin pathway involved in hunger and fullness. $NVO

🚀 $NVO: Wegovy Pill Hits New U.S. Prescription Record! Novo Nordisk’s oral Wegovy continues its strong momentum, reaching 217,050 weekly prescriptions in Week 42, up 4.2% from 208,304 the previous week, according to Symphony Health data cited in a Bloomberg-related report. Meanwhile, Eli Lilly’s $LLY Foundayo recorded 29,155 prescriptions, up 6.0% from 27,507. 📈 Wegovy now leads Foundayo by approximately 7.4 to 1 in reported weekly prescriptions. While both treatments are growing, Novo Nordisk maintains a commanding lead in this dataset. Importantly, Symphony Health’s figures may not fully capture online pharmacies and telehealth channels, meaning actual prescription volumes could be higher. The figures still require independent verification, and prescriptions do not directly translate into revenue. With Novo Nordisk’s Q3 earnings approaching on November 4, oral Wegovy’s commercial momentum could become an important focus for investors. $NVO $LLY #Wegovy #Obesity #NovoNordisk

$NVO Novo Nordisk Q3 Earnings: - Adj Sales: DKK79.20B (est DKK73.55B) - Adj Net: DKK25.60B (est DKK21.47B) - Sees FY Adjusted Sales At CER: -2% To +2% (est -2.35%) - Sees FY Adjusted Operating Profit At CER: -2% To +2% - Ozempic Sales: DKK29.71B (est DKK27.19B)

🚨 $NVO vs $LLY | Foundayo MISS! Eli Lilly’s obesity pill Foundayo missed Q3 sales expectations by nearly 20%. 📉 Actual sales: $184M 📊 Wall Street estimate: $229M ❌ Miss: −19.7% Novo Nordisk’s oral Wegovy continues to dominate the US obesity pill market in prescription volumes. $NVO $LLY

$NVO Let me tell you exactly what's going to happen and what you guys are going to do. Slowly but surely, we'll approach the Q3 er report. Until then, the market will consolidate, and we'll reach earnings day somewhere between $38 and $44. Then the report drops and everyone is blown away by the massive beat (which shouldn't be a surprise, since the sales data already point to it). The stock suddenly takes off, climbing toward $55–60 within a matter of weeks. And that's when you guys start taking profits right in the middle of the rally, or, if that's your entry price, you immediately run for the exit the moment you're finally back at breakeven. Meanwhile, NVO will steadily march its way above $100, but you guys will be nowhere to be found. You'll have been out of the stock for ages. People, give this company 1–2 years and you'll witness something incredible. And it's not magic. It's simply the end of the massive sell-off and undervaluation, followed by a recovery in confidence.

$NVO gonna crush earnings and the ceo is gonna say some sh*t like “we will experience some more headwinds due to unforeseen circumstances”

$NVO watching this and solar stocks. Might be some rotation into politically motivated beaten down stocks. Will wait to see how this holds up at market open before starting a position.$ENPH $FSLR

$NVO if the dems take over. This is lined up perfectly with a major pump with earnings ahead

$NVO don’t forget about earnings tomorrow in precum market . They will beat earnings and give good guidance and it will tank

$NVO it's time to burn the shorts. Fantastic earnings will push the stock. Now if the current pipeline have impressive or great results NOVO will rocket

$NVO in case it was not clear how absolutely manipulated the Stockmarket is. The Last US institutional Upgrade was at March 2024 the price hit that year almost 150. Since then Revenue +52%, Net profit +50 % Stock price more than -70 % . Let that sink in. Those Experts explaining the unexplainable ,make it just more laughable.

$NVO good rebound as treasury yields drop, rotation out of Ai and tech, and realization of how undervalued Novo is - then add in 1. High likelihood of earnings beat first week of November and raised forecasts and 2. Strong chance of positive FDA news any day over next 8-10 weeks - the setup could be for this to rocket back towards $50+